Question explored with the scientific record
Conversation so far
- 1 are some peptides more inheritantly dangerous than others
- 2 are some peptides more inheritantly dangerous than others specifically those that raise hgh
- 3 what are the common peptides that increase hgh
Answered on this page ↓
what are the common peptides that increase hgh
The short version: the peptides people actually buy to raise growth hormone are GHRP-6, GHRP-2, hexarelin, ipamorelin, and MK-677, and the human evidence on any of them is thin.
The named ones in this evidence are GHRP-6, GHRP-2, hexarelin, and MK-677 [1][2][3][5][6]. GHRP-6 and GHRP-2 work at the pituitary and raise GH release in lab and animal tissue [1][3]. Hexarelin, given as a nasal spray three times a day to eight short children for up to eight months, raised IGF-1 and growth velocity [5]. MK-677 is the only one with a large human trial, and it raised IGF-1 about 60% at six weeks and 73% at a year [6].
| Peptide | Human data here | What it showed |
|---|---|---|
| MK-677 | ~560 patients, 12 months [6] | IGF-1 up ~73%; blood sugar up |
| Hexarelin | 8 short children [5] | IGF-1 and growth velocity up |
| GHRP-6 | Animal and cell only [1][4] | GH release up |
| GHRP-2 | Ovine pituitary cells [3] | GH release up |
None of these trials measured the outcomes a healthy adult cares about: body composition, strength, or long-term cancer risk. The MK-677 Alzheimer's trial found no clinical benefit despite the IGF-1 rise [6], and a hip-fracture trial was stopped early over a heart-failure signal [7]. The GHRP-6 data is animal and cell work, not proof in people [1][4].
My call: these are the common GH-raising peptides, but only MK-677 has real human safety data, and it shows a blood-sugar cost with no proven benefit. Confidence: moderate on the list, low on long-term safety.
Sources used 7
-
Effects in vitro of New Growth Hormone Releasing Peptide (GHRP‐1) on Growth Hormone Secretion from Ovine Pituitary Cells in Primary Culture
This study investigates the effects of a newly synthesized growth hormone-releasing peptide (GHRP-1) on growth hormone secretion from ovine pituitary cells in primary culture, comparing its potency and mechanism of action to that of GHRP-6 and growth hormone-releasing factor (GR…
DOI: 10.1111/j.1365-2826.1994.tb00571.x -
Nonpeptide and Peptide Growth Hormone Secretagogues Act Both as Ghrelin Receptor Agonist and as Positive or Negative Allosteric Modulators of Ghrelin Signaling
In transfected cell assays, ghrelin receptor agonists differed in intrinsic signaling and allosterically modulated ghrelin: L-692,429 was positive, MK-677 neutral on potency but increased maximal response, and GHRP-6 negative.
DOI: 10.1210/me.2005-0059 -
Effect of GHRH and GHRP-2 treatment in vitro on GH secretion and levels of GH, pituitary transcription factor-1, GHRH-receptor, GH-secretagogue-receptor and somatostatin receptor mRNAs in ovine pituitary cells
This study investigates the effects of GHRH and GHRP-2 on GH secretion and the expression of related mRNAs in ovine pituitary cells, revealing a time-dependent regulation of GH and its receptors.
DOI: 10.1530/eje.0.1500235 -
Effects of growth hormone-releasing peptides in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism
The study investigates whether ghrelin and growth hormone-releasing peptide-6 (GHRP-6) stimulate GH, ACTH, and cortisol in healthy dogs and in dogs with pituitary-dependent hyperadrenocorticism (PDH), showing GH stimulation in healthy dogs but blunted GH response in PDH, with no…
DOI: 10.1016/s0303-7207(02)00293-9 -
Intranasal administration of the GHRP hexarelin accelerates growth in short children
In eight prepubertal, constitutionally short children, thrice-daily intranasal hexarelin over 3–8 months stimulated GH/IGF-I axis, increased linear growth velocity, raised IGF-I and certain metabolic markers, reduced subcutaneous fat, slightly increased head circumference, and w…
DOI: 10.1111/j.1365-2265.1995.tb02929.x -
Growth hormone secretagogue MK-677
A large, multicenter, double-blind randomized trial found that the growth hormone secretagogue MK-677 (ibutamoren) increased serum IGF-1 but did not slow the clinical progression of Alzheimer's disease over 12 months compared with placebo in individuals with mild-to-moderate AD.
DOI: 10.1212/01.wnl.0000335163.88054.e7 -
MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: A multicenter, randomized, placebo-controlled phase IIb study
A multicenter, randomized, double-blind phase IIb trial in 123 elderly hip-fracture patients tested MK-0677 (ibutamoren mesylate) 25 mg daily vs placebo for 24 weeks; IGF-1 rose markedly and some lower-extremity function signals appeared, but primary functional endpoints were no…
DOI: 10.1016/j.archger.2010.10.004